Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) and ProKidney (NASDAQ:PROK – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.
Insider and Institutional Ownership
12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 20.8% of Oramed Pharmaceuticals shares are held by insiders. Comparatively, 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Oramed Pharmaceuticals and ProKidney”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oramed Pharmaceuticals | $2.00 million | 81.52 | $64.05 million | $4.12 | 0.95 |
| ProKidney | $818,000.00 | 434.27 | -$68.99 million | ($0.55) | -2.14 |
Oramed Pharmaceuticals has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Oramed Pharmaceuticals and ProKidney’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oramed Pharmaceuticals | N/A | -5.17% | -4.54% |
| ProKidney | -10,288.39% | N/A | -27.39% |
Volatility and Risk
Oramed Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and price targets for Oramed Pharmaceuticals and ProKidney, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oramed Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
| ProKidney | 1 | 0 | 2 | 1 | 2.75 |
ProKidney has a consensus price target of $10.00, indicating a potential upside of 751.06%. Given ProKidney’s higher possible upside, analysts plainly believe ProKidney is more favorable than Oramed Pharmaceuticals.
Summary
ProKidney beats Oramed Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
About ProKidney
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
